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Using both in vitro (hippocampal synaptosomes in superfusion) and in vivo (microdialy-
sis) approaches we investigated whether and to what extent β amyloid peptide 1–40 (Aβ
1–40) interferes with the cholinergic modulation of the release of glycine (GLY) in the rat
hippocampus. The nicotine-evoked overflow of endogenous GLY in hippocampal synapto-
somes in superfusion was significantly inhibited by Aβ 1–40 (10 nM) while increasing the
concentration to 100 nM the inhibitory effect did not further increase. Both the Choline
(Ch; α7 agonist; 1 mM) and the 5-Iodo-A-85380 dihydrochloride (5IA85380, α4β2 agonist;
10 nM)-evoked GLY overflow were inhibited by Aβ 1–40 at 100 nM but not at 10 nM con-
centrations. The KCl evoked [3H]GLY and [3H]Acetylcholine (ACh) overflow were strongly
inhibited in presence of oxotremorine; however this inhibitory muscarinic effect was not
affected by Aβ 1–40. The effects of Aβ 1–40 on the administration of nicotine, veratridine,
5IA85380, and PHA543613 hydrochloride (PHA543613; a selective agonist of α7 subtypes)
on hippocampal endogenous GLY release in vivo were also studied. Aβ 1–40 significantly
reduced (at 10µM but not at 1µM) the nicotine-evoked in vivo release of GLY. Aβ 1–40 (at
10µM but not at 1µM) significantly inhibited the PHA543613 (1 mM)-elicited GLY overflow
while was ineffective on the GLY overflow evoked by 5IA85380 (1 mM). Aβ 40–1 (10µM) did
not produce any inhibitory effect on nicotine-evoked GLY overflow both in the in vitro and
in vivo experiments. Our results indicate that (a) the cholinergic modulation of the release
of GLY occurs by the activation of both α7 and α4β2 nicotinic ACh receptors (nAChRs) as
well as by the activation of inhibitory muscarinic ACh receptors (mAChRs) and (b) Aβ 1–40
can modulate cholinergic evoked GLY release exclusively through the interaction with α7
and the α4β2 nAChR nicotinic receptors but not through mAChR subtypes.
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INTRODUCTION
Nicotinic and muscarinic receptors are widely expressed in the
brain and implicated in the pathophysiology of many neurologi-
cal conditions, including Alzheimer’s disease (AD), where typical
symptoms include the loss of cognitive function and dementia.
The presence of extracellular neuritic plaques composed of β
amyloid (Aβ) peptide is a characteristic feature of AD, however,
although neurotoxicity is a prominent feature of Aβ, recent data
emphasize the existence of synaptic functional roles of this pep-
tide which can modulate the release of several neurotransmitters
(see Mura et al., 2012 and references therein). Accordingly, Aβ
isoforms and oligomers of increasing molecular dimensions may
have different biological actions in a continuum from physiology
to pathology, determining loss and gains of function along the
course of the disease (Mura et al., 2010a). Indeed, it has been
shown that non-neurotoxic Aβ 1–40 concentrations were able
to modulate (predominantly, but not exclusively, to inhibit) the
release of several neurotransmitters (dopamine, γ aminobutyric
acid, aspartate, glutamate) elicited by the stimulation of choliner-
gic muscarinic and nicotinic receptor [muscarinic ACh receptors
(mAChR); nicotinic ACh receptors (nAChR)] subtypes in different
brain areas; (Preda et al., 2008; Puzzo et al., 2008; Grilli et al., 2009;
Jürgensen and Ferreira, 2010;Mura et al., 2010a,b, 2012; Ondrej-
cak et al., 2010). The hippocampus, an area which is particularly
vulnerable and early target of Alzheimer’s disease and in which
the cholinergic pathways are critical for modulation of attention
and memory (Parri et al., 2011), Aβ regulates the nicotine-evoked
release of both excitatory (glutamate and aspartate) and inhibitory
(γ aminobutyric acid) aminoacids (Mura et al., 2012).
Increasing evidence demonstrate that glycine (GLY) is an
important aminoacid at hippocampal level which may have a dual
role acting as an inhibitory neurotransmitter, when interacting
with the strychnine-sensitive receptors, and playing a stimula-
tory role, when co-activating excitatory N -Methyl-d-aspartic acid
receptors together with glutamate (Johnson and Ascher, 1987; Luc-
cini et al., 2008; Romei et al., 2009, 2011; Zappettini et al., 2011). No
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data are available so far on the possible effects of Aβ on the cholin-
ergic receptors which modulate GLY release at the hippocampal
level.
In the present study using both in vitro (hippocampal synap-
tosomes in superfusion) and in vivo (microdialysis) approaches
we investigated whether and to what extent Aβ interferes with
the cholinergic modulation of the release of GLY in the rat
hippocampus.
The results indicate that (a) the cholinergic modulation of the
release of GLY occurs by the activation of both α7 and α4β2
(nAChRs) as previously reported (Zappettini et al., 2011) as well as
by the activation of inhibitory mAChRs; (b) the nicotinic modula-
tion of GLY release by α4β2, and α7 nAChRs is inhibited in vitro in
presence of a nanomolar concentration of Aβ 1–40 which is on the
contrary ineffective on the inhibitory mAChR receptor subtypes.
MATERIALS AND METHODS
ANIMALS
Adult male Wistar rats (200–250 g, Harlan, Udine) were used
for both in vivo experiments and as brain tissue source for
in vitro experiments. Animals were housed at constant temper-
ature (22± 1˚C) and relative humidity (50%) under a regular
light–dark schedule (light 7 a.m. to 7 p.m.). The in vitro exper-
imental procedures were approved by the Ethical Committee of
the Pharmacology and Toxicology Section, Department of Exper-
imental Medicine, in accordance with the European legislation
(European Communities Council Directive of 24 November 1986,
86/609/EEC) and were approved by Italian legislation on animal
experimentation (Decreto Ministeriale number 124/2003-A). The
in vivo protocol was approved by Ethical Committee of Pavia’s
University (registered as 2/2008) according to international reg-
ulations for the care and treatment of laboratory animals, to the
Italian Act (DL n 116, GU, suppl 40, 18 February, 1992) and to
EEC Council Directive (86/609, OJ L 358, 1, 12 December, 1987).
All efforts were made to minimize animal suffering and to use the
minimal number of animals necessary to produce reliable results.
IN VITRO EXPERIMENTS
Experiments of release
Rats were killed by decapitation and the hippocampus rapidly
removed at 0–4˚C. Purified synaptosomes were prepared on Per-
coll® gradients (Sigma-Aldrich, St Louis, MO, USA) essentially
according to (Nakamura et al., 1993), with only minor modifica-
tions. Briefly, the tissue was homogenized in six volumes of 0.32 M
sucrose, buffered at pH 7.4 with Tris–HCl, using a glass-teflon
tissue grinder (clearance 0.25 mm, 12 up–down strokes in about
1 min). The homogenate was centrifuged (5 min, 1000× g at 4˚C)
to remove nuclei and debris; the supernatant was gently stratified
on a discontinuous Percoll® gradient (2, 6, 10, and 20% v/v in
Tris-buffered sucrose) and centrifuged at 33,500× g for 5 min at
4˚C. The layer between 10 and 20% Percoll® (synaptosomal frac-
tion) was collected, washed by centrifugation, and resuspended in
physiological HEPES-buffered medium having the following com-
position (mM): NaCl 128, KCl 2.4, CaCl2 3.2, KH2PO4 1.2, MgSO4
1.2, HEPES 25, pH 7.5, glucose 10, pH 7.2–7.4 (Lu et al., 1998).
Synaptosomal protein content following purification was 10–15%
of that in the supernatant stratified on the Percoll® gradient.
The synaptosomal suspension was layered on microporous
filters at the bottom of a set of parallel superfusion chambers
maintained at 37˚C (Raiteri and Raiteri, 2000; Superfusion System,
Ugo Basile, Comerio, Varese, Italy). Synaptosomes were super-
fused at 1 ml/min with standard physiological medium as previ-
ously described. The system was first equilibrated during 36.5 min
of superfusion; subsequently, four consecutive 90 s fractions of
superfusate were collected and the endogenous GLY content was
measured by high performance liquid chromatography as below
described. Synaptosomes were exposed to agonists for 90 s starting
from the second fraction collected (t = 38 min), with antagonists
being added 8 min before agonists. The evoked overflow was cal-
culated by subtracting the corresponding basal release from each
fraction and was expressed as pmol/mg of synaptosomal proteins.
We previously demonstrated that in our superfusion system the
indirect drug effects exerted by other mediators in the monolayer
of synaptosomes in superfusion are absolutely minimized (Raiteri
and Raiteri, 2000).
When studying the release of [3H]GLY or [3H]Acetylcholine
(ACh) hippocampal synaptosomes were incubated for 20 min at
37˚C with [3H]GLY (final concentration 0.1µM) in the pres-
ence of the selective GLY transporter 1 transporter blocker N -
[(3R)-3-([1,1′-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N -
methylglycine hydrochloride (final concentration 0.3µM) or with
[3H]Choline (Ch, final concentration 0.08µM). The K+-induced
overflow from synaptosomes was estimated by subtracting the
neurotransmitter content into the first and the third fractions col-
lected (basal release, b1 and b3) from that in the 6-min fraction
collected during and after the depolarization pulse (evoked release,
b2). The amount of radioactivity released into each superfusate
fraction was expressed as a percentage of the total synaptosomal
tritium content at the start of the fraction collected (fractional
efflux).
ENDOGENOUS GLY DETERMINATION
Endogenous GLY was measured by high performance liquid chro-
matography analysis following precolumn derivatization with o-
phthalaldehyde and resolution through a C18-reverse phase chro-
matographic column (10 mm× 4.6 mm, 3µm; Chrompack, Mid-
dleburg, The Netherlands) coupled with fluorometric detection
(excitation wavelength 350 nm; emission wavelength 450 nm).
Homoserine was used as internal standard. Buffers and gradient
program were prepared and executed as follows: solvent A, 0.1 M
sodium acetate (pH 5.8)/methanol, 80:20; solvent B, 0.1 M sodium
acetate (pH 5.8)/methanol, 20:80; solvent C, sodium acetate (pH
6.0)/methanol, 80:20; gradient program, 100% C for 4 min from
the initiation of the program; 90% A and 10% B in 1 min; 42% A
and 58% B in 14 min; 100% B in 1 min; isocratic flow 2 min; 100%
C in 3 min; flow rate 0.9 ml/min.
IN VIVO EXPERIMENTS
Microdialysis probe implantation
Rats were anesthetized with Equithesin 3 ml/kg (pentobarbital
9.7 g, chloral hydrate 42.5 g, MgSO4 21.3 g for 1 l, 10% ethanol,
40% propylene glycol v/v) administered intraperitoneally and
placed in a stereotaxic apparatus (David Kopf Instruments,
Tujunga, CA, USA). The skin was shaved, disinfected, and cut
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with a sterile scalpel to expose the skull. A hole was drilled to allow
the implantation of the probe into the brain parenchyma. The
probe was implanted in the hippocampus (CA1/CA2 regions; AP
−5.8 mm, ML± 5.0 mm from bregma, and DV −8.0 mm from
dura) according to the Paxinos and Watson (1986) atlas, and
secured to the skull with one stainless steel screw and dental
cement. All in vivo experiments were performed using micro-
dialysis probes, made in our laboratory according to the original
method described by Di Chiara (1990; Emophan Bellco Artificial
OR-internal diameter 200µm, cutoff 40 kDa; Bellco, Mirandola,
Modena, Italy), with a nominal active length of 5 mm. Finally,
the skin was sutured, and the rats were allowed to recover from
anesthesia for at least 24 h before the neurotransmitter release
study.
Microdialysis samples collection
Microdialysis experiments were performed on conscious freely
moving rats. On the day of the experiments (24 h after the surgical
procedure), the probe was perfused with artificial CSF contain-
ing 145 mM NaCl, 3.0 mM KCl, 1.26 mM CaCl2, 1.0 mM MgCl2,
1.4 mM Na2HPO4, buffered at pH 7.2–7.4, and filtered through a
Millipore 0.2µm pore membrane. In all experiments, the micro-
dialysis membrane was allowed to stabilize for 1 h at the flow
rate of 4µl/min, without collecting samples. At the end of the
stabilization period, three samples were collected to evaluate base-
line release of GLY and then the specific treatment started. All
treatments were administered by manually switching syringes and
tubing connections to allow drugs diluted in artificial CSF to
flow through the probes. Tubing switches were performed tak-
ing care to maintain constant flow rates and collection volumes.
Both basal and treatment samples were collected every 20 min
in 100µl Eppendorf tubes. The flow rate of 4µl/min was main-
tained using a 1000-µl syringe (Hamilton) and a microinjection
pump (CMA/100, CMA/Microdialysis AB). In vitro recovery of
the probe for GLY was about 20%. Each rat was used for only
one microdialysis session. At the end of each experiment ani-
mals were sacrificed by guillotine, rat brains were removed and
the position of the microdialysis probe was verified by histo-
logical procedures, slicing the tissues by a cryostat microtome
(LEICA CM 1510). Only data from rats in which probe tracks
were exactly located in the target area were used for statistical
analysis.
Immunohistochemical analysis
Immunohistochemical analysis was performed to verify the pres-
ence of Aβ in the perfused tissue and to confirm (according to
HOECHST 33342 staining) the absence of neurotoxic-induced
apoptotic phenomenon. Brain tissue samples were frozen and
stored at −80˚C. For immunodetection of infused Aβ peptide,
10µm coronal sections (obtained on a cryostat Leica CM 1510)
were incubated with a primary monoclonal antibody recogniz-
ing Aβ protein (clone 4G8; Chemicon International). Sections
were then incubated with a mouse anti-IgG antibody RPE con-
jugated (Dako). After the fluorescent labeling procedures, sections
were finally counterstained for DNA with HOECHST 33342
and mounted in a drop of Mowiol (Calbiochem, Inalco SpA,
Milan, Italy). Fluorescent micrographs were acquired with a Leica
TCS SP5 II confocal microscope. After acquisition of fluorescent
micrographs, the slides were demounted and then the same
sections were slightly counterstained with Mayer hematoxylin,
dehydrated, and mounted in DPX for microanatomical analysis.
The images were acquired with a BX51 Olympus microscope.
STATISTICAL ANALYSIS
In vitro experiments
Multiple comparisons were performed with one-way ANOVA fol-
lowed by an appropriate post hoc test (Dunnett and Bonferroni).
Data were considered significant for p< 0.05, at least.
In vivo experiments
Values were expressed either as amount of GLY measured in the
dialyzate (pmol/80µl) or as area under the curve (AUC), evaluat-
ing the cumulative release over time. AUC was used as a measure
of treatment exposure and was calculated, for each animal, using
GraphPad Prism (version 4.03 GraphPad Software, San Diego, CA,
USA), defining as baseline of the area the basal value (average con-
centration of three consecutive samples immediately preceding the
drug dose).
D’Agostino–Pearson Omnibus Test (GraphPad Prism, version
4.03, GraphPad Software, San Diego, CA, USA) and Grubb’s
Test (GraphPad QuickCalcs, online calculator for scientists at
http://www.graphpad.com/quickcalcs/, GraphPad Software, San
Diego, CA, USA) were used as preliminary tests in order to evalu-
ate whether data were sampled from a Gaussian distribution and
to detect outliers respectively. All outliers were excluded from the
analysis. Data were then analyzed by analysis of variance (one-
or two-way ANOVA) followed, when significant, by an appropri-
ate post hoc comparison test. Data were considered significant for
p< 0.05. The reported data are expressed as means± SEM. The
number of animals used for each experiment is reported in the
legend to figures.
PREPARATION OF BETA AMYLOID SOLUTIONS
In the case of both in vivo and in vitro experiments, synthetic
human Aβ 1–40 (Sigma-Aldrich, Milan, Italy) was dissolved in
aCSF at a concentration of 100 mM (stock solution). Then, this
solution was filtered through a Millipore 0.2µm pore membrane
and stocked in small aliquots. Working solutions were freshly
prepared by diluting an aliquot of Aβ 1–40 stock solution at
the final concentrations (10 mM, 1 mM, or 100 nM Aβ 1–40 for
in vivo experiments, 100 nM, 10 nM, 1 nM, or 100 pM for in vitro
analysis).
CHEMICALS
Beta amyloid (1–40; 40–1), percoll®, choline, himbacine, dimethyl
sulfoxide, veratridine, nicotine hydrogen tartrate salt (Sigma-
Aldrich, St Louis, MO, USA); NFPS (ALX 5407), 5IA85380,
PHA543613, AQRA741 (Tocris Bioscience, Bristol, UK); all salts
used for the preparation of aCSF (NaCl, KCl, CaCl2, MgCl2,
Na2HPO4) and for Equithesin (MgSO4) were purchased at Merck
KGaA, Darmstadt, Germany; chloral hydrate, ethanol 96%, and
propylene glycol were used for the preparation of Equithesin and
were obtained at VWR BDH Prolabo, Belgium;[3H]Choline (spe-
cific activity: 60–90 Ci/mmol) and [3H]Glycine (specific activity:
15 Ci/mmol) were purchased from Perkin Elmer SpA.
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RESULTS
It is known that Aβ peptides structure and aggregation properties
depend on several factors. It is therefore important when using Aβ
peptides to specify both the concentration of the soluble Aβ but
also the methods used to prepare Aβ solution and to verify the
presence of Aβ aggregates (see Parri et al., 2011). This facilitates
the interpretation of the results when reporting on Aβ effects and,
which is even more important, would facilitate the comparison
of data obtained in different laboratories. Hence, in our previous
paper we characterized the Aβ peptide conformation we adminis-
tered in vivo by Western Blot procedure (Mura et al., 2012) showing
that we administered, at least predominantly, Aβ monomers. We
cannot completely exclude by the adopted methods that small
amounts of Aβ oligomers are present and may participate to pro-
duce the observed effects. In regard to the in vitro Aβ preparations,
since we did not observe aggregation at the concentrations and the
timing (up to 40 min) analyzed in vivo, we also do not expect to
observe aggregation at the lower concentrations and shorter times
used in vitro in light of the fact that aggregation is a concentration
and time-dependent process.
Figure 1A shows that the nicotine-evoked overflow of endoge-
nous GLY was significantly inhibited by Aβ 1–40 already at a
concentration of 10 nM while increasing the concentration to
100 nM the inhibitory effect did not further increase. The 1-nM
Aβ 1–40 concentration was ineffective. The reverse peptide Aβ
40–1 was ineffective even at high (100 nM) concentration. Aβ 1–
40 (100 nM) did not affect the veratridine (10 nM)-evoked GLY
overflow.
Since it has been shown that two different nAChR subtypes,
α7 and α4β2, modulate GLY release (Zappettini et al., 2011), the
possibility that Aβ may differentially inhibit the nicotinic con-
trol of GLY release has been investigated. In order to verify this
point we have studied the effects of two different agonists, Ch and
5-IA85380 hydrochloride (5IA85380), known to act selectively on
theα7 andα4β2 nAChR subtypes respectively (Mukhin et al., 2000;
Uteshev et al., 2003; Dickinson et al., 2007; Zappettini et al., 2010).
Ch (1 mM) and the 5IA85380 (10 nM)-evoked a similar overflow
of GLY confirming the involvement of the two receptor subtypes.
Both the Ch (1 mM) and the 5IA85380 (10 nM)-evoked GLY over-
flow were significantly inhibited by Aβ 1–40 at 100 nM but not at
10–1 nM concentrations compared to controls (Figure 1B). Aβ 1–
40 (100 nM) did not modify the basal release of endogenous GLY
(data not shown).
It has been demonstrated that also different mAChR sub-
types are involved in the modulation of both ACh and GLY
release from brain hippocampal synaptosomes (Raiteri et al., 1984;
Russo et al., 1993). We investigated whether Aβ was able to affect
the muscarinic control of the release of these two transmitters
as it was able to disrupt the nicotinic control of GLY release.
Figure 2A shows that the KCl evoked [3H]GLY overflow was
strongly inhibited in presence of oxotremorine. This inhibitory
effect was totally antagonized by himbacine but was not affected
by Aβ 1–40 (100 nM). In presence of oxotremorine also the KCl
evoked release of [3H]ACh from hippocampal nerve endings was
significantly inhibited (Figure 2B). This result was unexpected but
demonstrates quite interestingly that the cholinergic muscarinic
modulation of GLY release could be different according to the
different brain areas or the different species studied since previ-
ous findings using human cortical nerve endings have shown a
potentiating effect of oxotremorine on GLY release (Russo et al.,
1993). Interestingly also the inhibitory effect of oxotremorine on
[3H]ACh release was antagonized, as expected, by the specific M2
mAChR antagonist AQRA741 but was not affected by Aβ 1–40
(100 nM; Figure 2B).
Based on the in vitro data we then analyzed the effects of Aβ 1–
40 on the administration of nicotine, veratridine, 5IA85380, and
PHA543613 hydrochloride (PHA543613, a selective agonist of α7
subtypes) on hippocampal GLY release in vivo. In order to test
whether the administration of Aβ 1–40 through the dialysis probe
allowed the delivery of the peptide to the tissue we performed an
immunohistochemical analysis. Figure 3 shows the presence of the
peptide for the two concentrations tested in vivo (1 and 10µM)
within the hippocampus. Despite the fact that we do not know the
exact amounts of Aβ reaching the tissue, there was a visible pos-
itive correlation between the concentration administered and the
signal of Aβ immunoreactivity in the tissue. Moreover, immuno-
histochemical analysis shows that no evident signs of apoptosis
were observed within the area of amyloid diffusion as shown by
Hoechst staining.
The choice of the concentration of the nicotinic choliner-
gic agonists to be delivered in vivo was derived from previous
data demonstrating that the administration by microdialysis of
50 mM nicotine was able to significantly increase the levels of GLY
in hippocampal extracellular compartment (Toth, 1996; Fedele
et al., 1998; Zappettini et al., 2011). As previously shown in our
experimental conditions 40 min-long administration of 50 mM
nicotine was able to greatly enhance GLY release from basal val-
ues. Figure 4A show that Aβ 1–40 significantly reduced (at 10µM
but not at 1µM) the nicotine-evoked in vivo release of GLY. Aβ
40–1 did not produce any inhibitory effect used at 10µM concen-
tration. The GLY overflow stimulated by veratridine was unaltered
in presence of Aβ 1–40 (Figure 4B). Then we compared the effects
Aβ 1–40 after exposure to the selective nAChRs agonists, 5IA85380,
and PHA543613. As shown in Figure 4C, Aβ 1–40 (at 10µM
but not at 1µM) significantly inhibited the PHA543613 (1 mM)-
elicited GLY overflow while was ineffective on the GLY overflow
evoked by 5IA85380 (1 mM).
DISCUSSION
It is expected that cognitive deficits and memory impairments
in AD patients could be related, at least in part, to Aβ mediated
decrease of cholinergic function (Wang et al., 2009a,b, 2010; Parri
et al., 2011). However it is still unclear whether these impairments
are a consequence of a loss of cholinergic neurons and a decrease
of nAChRs or of a direct molecular interaction of Aβwith nAChRs
leading to a dysregulation of receptor function or of both mech-
anisms. To shed some light on these mechanisms we investigated
in the present study as well as in previous researches whether Aβ,
at concentrations not producing acutely neurotoxicity, is able to
disrupt the cholinergic control of neurotransmitter release. To do
this we took advantage of the fact that both α4β2, and α7 nAChRs
receptors are known to be expressed in rat hippocampal interneu-
rons (McQuiston and Madison, 1999; Sudweeks and Yakel, 2000;
Yakel and Shao,2004),and it is well-known that they have a positive
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FIGURE 1 | (A) Shows the concentration dependence effects of Aβ on
nicotine- and veratridine-evoked endogenous GLY overflows from rat
hippocampal synaptosomes. Data are mean±SEM of three to six
experiments for each concentration run in triplicate. *p<0.05 versus
nicotine-evoked GLY overflow (one-way ANOVA followed by Bonferroni
post hoc Test). (B) Shows the concentration dependence effects of Aβ on Ch
and 5IA85380 evoked endogenous GLY overflows from rat hippocampal
synaptosomes. Data are mean±SEM of three to six experiments for each
concentration run in triplicate. *p<0.05 versus Ch-evoked GLY overflow
(one-way ANOVA followed by Dunnett’s Multiple Comparison Test).
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FIGURE 2 | (A) Shows the effects of Aβ on muscarinic receptors
controlling KCl evoked [3H]GLY overflow from rat hippocampal
synaptosomes. Data are mean±SEM of three to six experiments run
in triplicate. *p<0.05; **p<0.01 versus KCl evoked [3H]GLY
overflow; ##p<0.01 versus KCl plus oxotremorine (1µM)-evoked
[3H]GLY overflow. (B) Shows the effects of Aβ on muscarinic
receptors controlling KCl evoked [3H]ACh overflow from rat
hippocampal synaptosomes. Data are mean±SEM of three to six
experiments run in triplicate. ***p<0.001 versus KCl evoked [3H]ACh
overflow; ##p<0.001 versus KCl plus oxotremorine (1µM) -evoked
[3H]ACh overflow (one-way ANOVA followed by Bonferroni post hoc
Test).
role in regulating cognitive function (Picciotto et al., 1995; Levin
and Simon, 1998). Being aware that several neurotransmitters that
play important roles in cognitive functions could be affected either
directly or indirectly by Aβ, we focused our attention on GLY.
Indeed increasing evidence demonstrate that GLY is an important
aminoacid at hippocampal level which has a dual role (a) act-
ing as an inhibitory neurotransmitter when interacting with the
strychnine-sensitive receptors and (b) playing a fundamental stim-
ulatory role when co-activating excitatory N -Methyl-d-aspartic
acid receptors together with glutamate (Johnson and Ascher, 1987;
Hirai et al., 1996; Luccini et al., 2008; Kubota et al., 2010; Zappet-
tini et al., 2011). The changes in the GLY release may therefore
directly interfere with glutamate neurotransmission, which plays
an important role in the processes of learning and memory in this
brain area.
We here report that the cholinergic modulation of GLY release
at the presynaptic level on hippocampal nerve endings was mod-
ulated not only by stimulatory α4β2 and α7 nAChRs as previously
reported (Zappettini et al., 2011) but also by an inhibitory, mAChR
subtype. We do not know whether both nicotinic and muscarinic
receptors are present on all nerve endings or they are peculiar of
a specific neuronal population and/or their physiological impor-
tance in the intact tissue. It is quite interesting however that the
two modulatory mechanisms display a different sensitivity to Aβ.
The stimulatory effects of both α4β2 and α7 nAChRs were par-
tially blocked by nanomolar concentration of Aβ 1–40 which was
on the contrary inactive on the mAChRs inhibiting GLY release.
This observation allows to speculate that an excess of Aβ (the range
of active concentrations was between 10 and 100 nM in vitro and
10µM in vivo) as it may happen because of the disease may dysreg-
ulate the cholinergic modulation of hippocampal activity leading
to a disproportionate inhibition since it leaves unaffected the mus-
carinic inhibitory control and impairs the nicotinic stimulatory
one. All this occurs in absence of Aβ acutely induced neuronal
damage.
The decreased release of GLY may have several functional con-
sequences. Some of them may be relevant to the development of
AD pathology. As an example, a decrease of GLY release may reduce
the tonic inhibition exerted through the activation of GLY recep-
tors (Mori et al., 2002; Petrini et al., 2004; Farrant and Nusser,
2005) normally providing neuroprotection under pathological
conditions, when extracellular GLY levels are elevated (Baker et al.,
1991; Saransaari et al., 1997; Zhao et al., 2005; Saransaari and Oja,
2008). A second relevant event caused by a reduced glycine release
may consist in a decrease of N -Methyl-d-aspartic acid receptors
co-activation. At this regard it is important to recall that intrac-
erebroventricular injection of Aβ 1–40 significantly suppress high
frequency stimulation-induced LTP (Chen et al., 2006; Wu et al.,
2008).
The exact nature of the Aβ interaction with nAChR subtypes is
so far not well understood.
Interestingly in our study both the α7 and the α4β2 nAChR
subtypes which almost equally contribute to the stimulation of
GLY release, were functionally inhibited in vitro apparently in
a similar extent by Aβ concentrations in the nanomolar range
(Figure 2B). However we do not know whether Aβ might have
Frontiers in Pharmacology | Neuropharmacology July 2012 | Volume 3 | Article 146 | 6
Zappettini et al. Beta amyloid and glycine release
FIGURE 3 | Immunohistochemical analysis showing the presence of
beta-amyloid (Aβ) in hippocampal tissue after the perfusion of the
peptide at two different concentrations. Coronal section indicating the
location of the microdialysis probe (hippocampus, black rectangle)
counterstained with Mayer Hematoxylin and relative fluorescence
micrographs of the area within the black rectangle showing the presence of
human Aβ protein. Aβ immunoreactivity (red-PE staining, white arrows)
immediately after perfusion of 10 and 1µM Aβ 1–40. Nuclear DNA was
counterstained with Hoechst 33,342 (blue staining). Scale bars for Mayer
hematoxylin sections: 200µM. Scale bars for fluorescent micrographs:
100µM.
a similar mechanism of action on the two different nAChR sub-
types. The inhibitory effect on both the α7 and the α4β2 nAChR
was incomplete with a maximal inhibition of about 30–40%. A
recently described allosteric binding pocket located within the
trans membrane domain of the α7 and of non-α7 nAChRs might
provide a potential structure-function mechanism to explain the
inhibitory effects of Aβ (Young et al., 2008; Gill et al., 2011, 2012).
Indeed Aβ at concentration in the upper nanomolar range
(10 nM) produced full effect while did not produced any effect
at 1 nM concentration. Ten nanomolars Aβ beyond the estimated
normal concentrations in human CSF but may be caused by the
altered precursor protein processing as it occurs along with the dis-
ease (Reaume et al., 1996) or be related to defects in the removal
of the peptide from the extracellular space as it may occur in the
disease in association with the ApoE ε4 genotype (Cramer et al.,
2012).
Of course talking about cholinergic modulation of GLY release
we have also to consider the possibility that Aβ might for instance
interfere directly with the mechanisms which modulate the release
of ACh. However our data show that Aβ was ineffective also on
the inhibitory muscarinic autoreceptors which inhibit ACh release
FIGURE 4 |The figure shows the in vivo effect of Aβ 1–40 on the
nicotine-, veratrine-, PHA543613-, and 5IA85380-induced overflow of
GLY, in rat hippocampus [(A–C) respectively]. Aβ 1–40 (10µM but not
1µM) significantly inhibited the 50-mM nicotine-induced overflow of GLY
*p<0.01 versus nicotine (one-way ANOVA followed by Dunnett’s Multiple
Comparison Test). Aβ 40–1 10µM was ineffective (A). Aβ 1–40 (10µM)
which significantly inhibited the 1-mM PHA543613-induced overflow of GLY
was unable to inhibit both the 100-µM veratridine- and the
5IA85380-induced overflow of GLY (B,C). Data are expressed as
mean±SEM of 4–15 individual rats for each experimental group. *p<0.01
versus PHA543613 (one-way ANOVA followed by Dunnett’s Multiple
Comparison Test.
(Figure 2). We can therefore foresee that in an integrated system,
where cellular networks and their functional relationships are
completely preserved and several direct and indirect processes are
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simultaneously taking place in neurons, the effect of Aβ on the
cholinergic modulation of GLY function may mostly depend on
the interaction of Aβ with the nAChRs.
Our findings in vivo largely support this view even if Aβ was
unable to inhibit the release of GLY elicited by the specific α4β2
nAChRs agonist while it exerted an inhibition (over 40%) of
both nicotine and PHA543613 stimulated GLY release. On the
other hand in vivo important differences were noticed at the
baseline in the ability of the two specific nAChRs agonists to
elicit GLY release as compare to in vitro. Indeed in vitro both
α7 and α4β2 nAChRs agonists were able to stimulate to the same
extent GLY release; while in vivo the release elicited by 5IA85380
was less than a half that obtained in response to PHA543613.
In vivo to many variables may take place, and in spite of the
above described discrepancy, there is a general good agreement
of the effects in vivo and in vitro of Aβ on the release of var-
ious neurotransmitters (present work and references) including
the observation that so far Aβ has never been able to modify
the depolarization (veratridine or potassium)-elicited release of
neurotransmitters, but only the one modulated by presynaptic
receptors.
In conclusion our findings show that Aβ can modulate choliner-
gic evoked GLY release exclusively through the interaction with α7
and the α4β2 nAChR nicotinic receptors, acting probably through
different mechanisms of action, but not through mAChRs. The
present study may therefore provide further insight into the mech-
anism by which AB impairs synaptic plasticity and cholinergic
function in AD brain.
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